Case report of three patients with end-stage recurrent glioblastoma treated with meldonium
The case reports presented here suggest good tolerability and the potential for meldonium to improve outcome in glioblastoma patients. Controlled clinical trials need to follow to evaluate systematically possible benefits from the integration of meldonium into standard glioblastoma treatment protocols.
Authors
- Martin Weidemeier (ORCID: https://orcid.org/0000-0002-3706-6551)
- Sandra Bien-Möller (ORCID: https://orcid.org/0000-0002-0603-8953)
- Mladen V. Tzvetkov (ORCID: https://orcid.org/0000-0003-1670-5534)
- Josefine Radke (ORCID: https://orcid.org/0000-0001-9860-2007)
- Stefan Engeli (ORCID: https://orcid.org/0000-0002-3087-971X)
- Henry Schroeder (ORCID: https://orcid.org/0009-0000-3275-9167)
- Jörg Baldauf
Institutions
- Universitätsmedizin Greifswald (DE)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-04-28
- DOI
- https://doi.org/10.1038/s44276-025-00124-7
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Stiftung Universitätsmedizin Essen